An update from the Leukemia & Lymphoma Society (LLS): A few awesome developments in acute myeloid leukemia (AML) treatment research that have occurred in the last few months – 3 new therapies have been recently approved by the FDA for patients living with AML!
- Midostaurin (RYDAPT): LLS funded much of the earlier preclinical and clinical work of researchers who helped identify the drug’s effectiveness in killing certain types of AML cells, Read more here: https://www.fda.gov/
NewsEvents/Newsroom/ PressAnnouncements/ucm555778. htm - Enasidenib (IDHIFA): Approval for AML patients who have relapsed or do not respond to standard chemotherapy. Read more here: http://www.lls.org/lls-
us-hq/news/fda-approves-new- targeted-therapy-for-aml?news= News%20Releases&newsid=12355 - Vyxeos (CPX-351): LLS has funded the development of this drug since 2009 through our Therapy Acceleration Program (TAP), in which we partnered with Celator Pharmaceuticals, the developer of Vyxeos! Read more here: http://www.lls.org/lls-
us-hq/news/lls-applauds- another-advance-for-blood- cancer-patients